- Selina seals reverse merger deal •
- Essentium shines with $974m reverse merger •
- Panther Labs roars to $120m series B •
- Lotte allots $68m to Wadiz series D •
- AviadoBio accesses $80m in series A funding •
- WeNext wins $55m in funding •
- Drone Fund 3 flies to final close •
- Daily Deal Round Up: December 2, 2021 •
- Powerlist Q&A – Sergio Escobar, BCF Ventures •
- Eswin rakes in $392m •
- 1inch Network broadcasts $175m series B round •
- Allegion Ventures allocates $100m to second fund •
Healthcare
AviadoBio accesses $80m in series A funding
AviadoBio is focusing on neurodegenerative diseases and has emerged from stealth with nearly $100m in total from investors including Johnson & Johnson Innovation – JJDC.
Curie Therapeutics comes out of stealth with $75m
Access Industries subsidiary Access Biotechnology co-led a round disclosed by the radiopharmaceutical drug developer as it publicly launched.
Daily Deal Round Up: December 1, 2021
Mercedes-Benz and Stellantis made strategic investments in advanced battery developer Factorial Energy while celluar therapy developer Mana Therapeutics closed its $42m series A round.
Harrison.ai captures series B funding
Sonic Healthcare and I-Med Radiology Network helped the smart diagnostics technology developer secure $91.6m that will be used to accelerate its expansion into new medical areas and scale its team.
HotSpot Therapeutics heats up with $100m
Merck & Co and SR One were among the investors in a series C round for the small molecule drug developer led by Pivotal BioVenture Partners.
Abogen accesses $300m
The vaccine developer's series C-plus round was co-led by SoftBank Vision Fund and came just three months after it closed a $700m series C.
Legend Capital lets in $177m for healthcare fund
The Legend Holdings-formed venture capital firm is reportedly seeking $300m for the final close of its latest dollar-denominated healthcare vehicle.
Ablaze Pharmaceuticals catches alight with $75m
Radiotherapy developer RayzeBio has spun off a China-focused subsidiary called Ablaze with series A funding from investors also including Nan Fung.
Other News
Lunit lassoes corporates to raise $61m
The medical technology developer increased its total funding to over $135m in a round backed by Naver, NSG Ventures, Kakao Ventures and SoftBank Ventures Asia.
Daily Deal Round Up: November 26, 2021
Fosun RZ Capital returned to reinvest in e-commerce software provider Desty through a $5m series A round while inventory management software developer Smart Shopping boosted its total funding to $14m.
Daily Deal Round Up: November 25, 2021
Bent Pixels co-led new media company Hepmil Media's first funding round while dating app developer East Meets East completed a DeNA-led series A.
Vision Medicals wins $47m
The medical technology developer received series D funding from investors including existing backer Tencent, pushing its total funding past $120m.
Stilla collects $35m
Illumina helped the digital PCR technology developer secure fresh convertible bond and loan financing that will be used for international expansion and the further development of its platform.
Luma Health hauls in $130m
The Texas Medical Center and Cisco-backed healthcare administration platform developer raised series C financing that took its overall funding to $160m.
Editor's Picks
Abbisko nabs $226m in IPO
AstraZeneca, Eli Lilly and Sinopharm all achieved exits as the cancer therapy developer listed on the Hong Kong Stock Exchange at a reported valuation of nearly $1.1bn.
PharmEasy reaps $350m pre-IPO funding
The Ascent Health and Wellness Solutions, Manipal Education and Medical Group, Medi Assist Healthcare Services and Prosus-backed online drugstore secured the funding at a $5.6bn valuation.
Headspace and Ginger decide on merger
The $3bn merger of meditation app developer Headspace and digital mental health services provider Ginger would present a new path for a plethora of corporate investors.
TScan takes in $100m through IPO
The Alphabet, Astellas, Novartis and WuXi AppTec-backed cancer therapy developer priced its shares at the foot of their range in an upsized offering.
About us
Global Corporate Venturing (GCV) is where global innovation and capital converge to define, invest and shape the world of tomorrow. We provide the world’s investors and the wider innovation ecosystem with the information, insights, collaboration and access they need to succeed in a constantly changing world.
Navigation
